Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Down 5.8% - Should You Sell?

Key Points

• DMRA shares fell 5.8% to $27.33 in mid-day trading, with volume down 90% from the average session.
• Analyst sentiment remains broadly positive: the stock has an average “Buy” rating and a consensus price target of $44, despite one “Sell” rating.
• The company reported a quarterly loss of $0.39 per share, beating expectations of a $0.45 loss; hedge funds and institutional investors own approximately 14.2% of outstanding shares.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) shares were down 5.8% on Monday . The stock traded as low as $27.33 and last traded at $27.33. 37,775 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 377,997 shares. The stock had previously closed at $29.00.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on DMRA. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research note on Monday, August 24th. HC Wainwright reissued a "buy" rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Wedbush upped their target price on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an "outperform" rating in a report on Thursday, July 30th. Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a "buy" rating and a $50.00 target price on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock currently has an average rating of "Buy" and an average target price of $44.00.

Damora Therapeutics, Inc. Common Stock Stock Down 8.4%

The firm has a market capitalization of $1.64 billion, a PE ratio of -7.88 and a beta of 1.47. The company's 50-day simple moving average is $29.22 and its 200 day simple moving average is $26.80.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.06. On average, sell-side analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Institutional investors and hedge funds have recently bought and sold shares of the company. Ikarian Capital LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $6,574,000. Boothbay Fund Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $2,204,000. Jain Global LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $2,774,000. Remedium Capital Partners LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $2,772,000. Finally, Geode Capital Management LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $266,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source